Interviews @ MSAPR Partners

Archive Interviews before 2022

Archive Interviews before 2011

Issue 984: February 16, 2024 Matt Kane, CEO and Director at Tune Therapeutics, on pioneering the next generation of epigenome editing.	Issue 982: February 2, 2024 Roger Hajjar, M.D., Director of MGB Gene and Cell Therapy Institute at Mass General Brigham, on streamlining the discovery and trials of innovative treatments.
Issue 981: January 26, 2024 Dr. Michael Crackower, Ph.D, Founder and Chief Scientific Officer at BrainChild Bio, Inc., on revolutionizing CAR T-cell therapy in CNS cancers.	Issue 980: January 19, 2024 Dr. Michael Jensen, M.D., Research Professor in the Center for Genetic Epidemiology, Department of Population and Public Health Sciences at Keck School of Medicine, University of Southern California, on her groundbreaking research on hyperemesis gravidarum and discovering the cause of the disease and identifying potential treatments.
Issue 976: December 22, 2023 Dr. Michael Crackower, Ph.D, Chief Scientific Officer at Ventus Therapeutics, on leveraging structural biology and computational chemistry tools to pioneer novel medicines.	Issue 972: November 17, 2023 Andrew Allen, M.D., Ph.D., Co-founder, President and CEO of Gritstone bio, on leading the way in developing next-generation vaccines.
Issue 968: October 13, 2023 Peter M. Tessier, Ph.D., Albert M. Mattocks Professor of Pharmaceutical Sciences and Chemical Engineering at the University of Michigan, on paving the way for the use of machine learning to optimize therapeutic antibodies.	Issue 963: September 8, 2023 Hamideh Parhiz, Pharm.D., Ph.D., Research Assistant Professor in the Division of Infectious Diseases at the Perelman School of Medicine at the University of Pennsylvania, on pioneering the frontier of targeted mRNA-based in vivo gene therapy.
Issue 961: August 25, 2023 Steve Uden, M.D. and Martin Mackay, Ph.D., Co-Founder and Chief Executive Officer of Rallybio and Co-Founder and Executive Chairman of Rallybio, on developing and delivering transformative therapies.	Issue 957: July 21, 2023 Gregg Silverman, M.D., Professor of Medicine and Pathology at NYU School of Medicine, on discovering the link between lupus and the gut microbiome.
Issue 952: June 16, 2023 Joseph Kim, Chief Strategy Officer of ProofPilot, on pioneering the digital automation of antibodies.	Issue 949: May 26, 2023 Matt Maisak, Ph.D., CEO of Covant Therapeutics, on leading the way in developing novel therapies.
Issue 948: May 19, 2023 John K. Celebi, President and CEO of Sensei Biotherapeutics, Inc., on pioneering the frontier of VISTA-inhibiting antibodies.	Issue 947: May 12, 2023 Rodney Varner, Co-founder, Chairman, and CEO of Genprex, Inc., on leveraging two novel gene therapies for cancer and diabetes.
Issue 943: April 14, 2023 Dan Passeri, M.Sc., J.D., CEO of Cue Biopharma, on developing the future of IL-2 therapies.	Issue 941: March 31, 2023 Tony Reid, M.D., Ph.D., CEO of EpicentRx Inc., on developing a very safe drug with multifaceted benefits.
Issue 938: March 3, 2023 Peter J. Chockley, PH.D, postdoctoral researcher at St. Jude Children’s Research Hospital, on optimizing the design of CARs with an anchoring protein.	Issue 932: January 20, 2023 David K. Barr, Esq., Partner at Stroock & Stroock & Lavan LLP, on intellectual property complexities in cell and gene therapies.
Issue 931: January 13, 2023 Ameet Nathwani, M.D., CEO of Dewpoint, on pioneering the frontier of condensate biology.	Issue 928: December 16, 2022 Chris Wasden, Ph.D., Chief Strategy Officer of Twill, on creating integrated care with digital therapeutics.